You just read:

PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna™ for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

News provided by

PTC Therapeutics, Inc.

Mar 06, 2017, 08:00 ET